Skip to main content
Biopsy from the tubular esophagus showing incomplete intestinal metaplasia, goblet cells with interposed cells having gastric foveolar-type mucin consistent with Barrett esophagus. Negative for dysplasia. H&E stain. Credit: Creative Commons

A team including researchers from the Department of Energy’s Oak Ridge National Laboratory has developed a digital tool to better monitor a condition known as Barrett’s esophagus, which affects more than 3 million people in the United States.

Larry Baylor, left, and Andrew Lupini have been elected fellows of the American Physical Society. Credit: ORNL, U.S. Dept. of Energy

ORNL's Larry Baylor and Andrew Lupini have been elected fellows of the American Physical Society.

The first central solenoid module arrived at the ITER site in St. Paul-lez-Durance, France on Sept. 9. Credit: ITER Organization

Staff at Oak Ridge National Laboratory organized transport for a powerful component that is critical to the world’s largest experiment, the international ITER project.

Summer Widner, Stephanie Timbs, James Gaugler and James Avenell of ORNL are part of a team that processes thorium-228, a byproduct of actinium-227. As new uses for thorium are realized, particularly in medicine, the lab expects the demand for the radioisotope to grow.

As a medical isotope, thorium-228 has a lot of potential — and Oak Ridge National Laboratory produces a lot.

Researchers studying secondary metabolites in the fungus Aspergillus flavus, pictured, found unique mixes of metabolites corresponding to genetically distinct populations. The finding suggests local environmental conditions play a key role in secondary metabolite production, influencing the discovery of drugs and other useful compounds. Credit: Tomás Allen Rush/ORNL, U.S. Dept. of Energy.

Scientists at ORNL and the University of Wisconsin–Madison have discovered that genetically distinct populations within the same species of fungi can produce unique mixes of secondary metabolites, which are organic compounds with applications in

For the first time in 25 years, scientists will use deuterium and tritium to create a plasma inside the chamber of the Joint European Torus in the United Kingdom to study nuclear fusion. As in the earlier experiments, diagnostics systems developed by ORNL will play a key role in monitoring the plasma. Credit: EUROfusion

Equipment and expertise from Oak Ridge National Laboratory will allow scientists studying fusion energy and technologies to acquire crucial data during landmark fusion experiments in Europe. 

An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus. Credit: Michelle Lehman/ORNL, U.S. Dept. of Energy

An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.

Belinda Akpa applies her diverse expertise and high-performance computing to accelerate the drug discovery process and increase the chances of success when candidate molecules go to clinical trials. Credit: Carlos Jones/ORNL, U.S. Dept. of Energy

Belinda Akpa is a chemical engineer with a talent for tackling big challenges and fostering inclusivity and diversity in the next generation of scientists.

Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.

Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.

ATOM logo

The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.